Introduction to Canine Health Innovations
In an exciting development for pet health, Scarecrow Incorporated has secured a groundbreaking patent for their animal supplement, Pinfenon (S) (R). This innovative product focuses on addressing cardiac disorders that often affect our beloved canine companions.
Understanding Pinfenon (S) (R)
The Patent Overview
The recent patent acquisition marks a significant milestone in veterinary medicine, covering both treatment and prophylactic drugs aimed at lowering cardiac disorder markers in dogs. Specifically, Pinfenon (S) (R) is designed to reduce levels of atrial natriuretic peptide (ANP), a critical biomarker linked to heart health.
Manufacturing Methods
Alongside its medical benefits, the patent also outlines advanced methods for the supplement's manufacturing. This combination ensures that products derived from Pinfenon can be utilized in various formats including foods, shampoos, and other health products aimed at small dogs.
The Significance of Mitral Regurgitation
Mitral regurgitation is a common cardiac issue in small dog breeds. It occurs when the heart’s mitral valve doesn't close tightly, leading to blood leakage and increased workload on the heart. This condition is particularly prevalent in certain breeds and poses serious health risks, including respiratory issues and eventual heart failure.
Link to Atrial Natriuretic Peptide
ANP is secreted when the heart is under stress. Measuring ANP levels has become a standard way to assess cardiac function in dogs, making it a significant focus in developing treatments that can safely alleviate these health concerns.
Clinical Evidence and Testing
Prior to the patent approval, a comprehensive clinical study was conducted on 27 dogs diagnosed with mitral regurgitation. Over the course of 30 days, these dogs were administered Pinfenon (S) (R) alongside their usual cardiac medications. The comparison of blood test results before and after the treatment provided compelling evidence supporting the supplement's efficacy.
Positive Outcomes Observed
The study indicated a notable reduction in ANP levels, as well as improvements in respiratory difficulties in the treated dogs. This not only highlights the potential for Pinfenon to make a meaningful difference in the lives of affected pets but also serves as a promising advance in canine healthcare.
Ingredients and Their Benefits
The main ingredient in Pinfenon (S) (R) is extracted from the bark of the French maritime pine, a natural source known for its high physiological activity. This water-soluble ingredient demonstrates significant health benefits and has been supported by extensive global research.
Supportive Ingredients
To enhance its efficacy, Pinfenon (S) (R) also incorporates fermented sesame extract and yeast extract. Together, these ingredients work synergistically to promote better health outcomes for dogs experiencing cardiac issues.
About Scarecrow Incorporated
Scarecrow Incorporated is dedicated to innovating pet health solutions. The company's commitment to research and development has positioned them at the forefront of veterinary science, focusing on improving the quality of life for dogs everywhere.
Frequently Asked Questions
What is Pinfenon (S) (R)?
Pinfenon (S) (R) is a patented animal supplement designed to aid in lowering cardiac disorder markers in dogs, particularly focusing on mitral regurgitation.
How does the patent benefit dog owners?
The patent ensures that the production methods for Pinfenon (S) (R) are standardized, providing dog owners with reliable and effective treatment options for cardiac health.
Was clinical testing conducted for this supplement?
Yes, a clinical study involving 27 dogs was conducted, showing significant improvements in cardiac biomarkers after the administration of Pinfenon (S) (R).
What are the ingredients in the supplement?
The main ingredient is extracted from French maritime pine, combined with fermented sesame extract and yeast extract for enhanced health benefits.
Who is behind the development of Pinfenon (S) (R)?
This innovative supplement was developed by Scarecrow Incorporated, with input from experienced researchers and veterinarians in the field.
